XIGDUO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xigduo, and what generic alternatives are available?
Xigduo is a drug marketed by Astrazeneca Ab and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in XIGDUO is dapagliflozin; metformin hydrochloride. There are twenty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xigduo
A generic version of XIGDUO was approved as dapagliflozin; metformin hydrochloride by ALKEM LABS LTD on April 6th, 2026.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for XIGDUO?
- What are the global sales for XIGDUO?
- What is Average Wholesale Price for XIGDUO?
Summary for XIGDUO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for XIGDUO |
| What excipients (inactive ingredients) are in XIGDUO? | XIGDUO excipients list |
| DailyMed Link: | XIGDUO at DailyMed |
US Patents and Regulatory Information for XIGDUO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-003 | Oct 29, 2014 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-004 | Oct 29, 2014 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-003 | Oct 29, 2014 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-003 | Oct 29, 2014 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-005 | Jul 28, 2017 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-001 | Oct 29, 2014 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
